Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.

Calcimimetic agents have recently been evaluated in the treatment of secondary hyperparathyroidism (SHPT) as add-on therapy to calcitriol and vitamin D analogues and dietary phosphate binders.